Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax ... Moderna's first bivalent shot mRNA-1273. ...

The new version – dubbed Spikevax Bivalent Original/Omicron – has been given conditional authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) based on phase 2/3 ...

Prior to using these logos, familiarize yourself with Saint Louis University's logo guidelines. Saint Louis University logo marks are copyrighted. Use of these logos is restricted to the Saint Louis ...

The vaccine will be Moderna’s second product to enter the U.S. market after the FDA’s approval of the biotech company’s COVID ...

Moderna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher ...

4 and BA.5 sub-variants. So far, the only bivalent vaccines developed and approved for use in humans are the adapted versions of Moderna Spikevax and Pfizer-BioNTech Comirnaty. People over 50 ...

On Thursday, the federal health regulator announced it has given the green light to Moderna's Omicron-targeting bivalent COVID-19 vaccine, for those ages 18 years and older. The "Spikevax Bivalent ...

Novavax's traditional protein-based shot offers an alternative vaccine technology to those that are based on messenger RNA - Moderna's Spikevax and Comirnaty, which is jointly developed by Pfizer ...

adding that the bivalent Moderna Spikevax booster is safe and effective with the same mild adverse reactions that resolved quickly, Xinhua news agency reported. Clinical trial results showed that ...

Moderna developed the Spikevax COVID-19 vaccine, and regulators approved this year its vaccine for RSV or respiratory syncytial virus. The company also has a combination flu/COVID vaccine and an ...

A Reddit thread started Thursday titled, "What's wrong with the Facebook logo?" shows a blue lowercase "f" on a black background instead of a blue background with a white "f." Some users who have ...

Until now, Canada has only had access to vaccine formulas that were approved in fall 2023 and target the Omicron XBB.1.5. Moderna's latest formulation of their mRNA vaccine, Spikevax, targets the KP.2 ...